- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07600814
Pain Induced by m-Cresol as Preservative
Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers
Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.
This study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background and Objective:
m-Cresol has been used since 1980 to limit bacterial growth in parenteral medications. Although it is generally considered safe, evidence for local side effects has appeared in case reports and a clinical trial where changing the preservative led to a disappearance of local discomfort. This suggests that the preservative itself, rather than the active drug or the pH of the solution, may be responsible for a pain sensation. The objective of this study is to systematically evaluate if subcutaneous injection of m-Cresol at clinically relevant concentrations causes pain in humans.
Study Design:
This is a randomized, double-blind, placebo-controlled, 3-period crossover trial in healthy volunteers (n=18). To ensure an unbiased assessment and control for potential order effects, a Williams balanced design is utilized for the randomization of treatment sequences.
Methodology:
Familiarization: Participants first receive an unblinded injection of control solution to become accustomed to the experimental procedure and the numerical pain rating scale.
Interventions: Subjects receive three randomized, double-blind 300 µl subcutaneous injections at different spots on a belly fold, separated by at least 3 cm. The treatments include:
- m-Cresol at 0.1%
- m-Cresol at 0.25%
- Control solution. Pain Assessment: For each injection, pain intensity is recorded every 5 seconds using a numerical pain rating scale (0-100) until no pain is reported for 30 consecutive seconds. The pain caused by the needle insertion itself is rated separately before the injection begins to serve as a covariate for the statistical analysis.
Statistical Analysis:
The primary endpoint is the Area Under the Curve (AUC) of the subjective pain ratings over time. Comparisons will be made between the different m-Cresol concentrations and the vehicle control using a linear mixed model to test the primary hypotheses.
Studietype
Inschrijving (Geschat)
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
- Naam: Felix J. Resch
- Telefoonnummer: +43 1 40160 31419
- E-mail: felix.resch@meduniwien.ac.at
Studie Contact Back-up
- Naam: Michael J.M. Fischer
- Telefoonnummer: +43 1 40160 31410
- E-mail: michael.jm.fischer@meduniwien.ac.at
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion criteria
- Age between 18 and 70 years
- Full legal capacity Exclusion criteria
- Participant of another study, ongoing or within the last four weeks
- Current medication intake (except hormonal contraception) or drug abuse
- Female subjects: Positive pregnancy test or breastfeeding
- Body temperature above 38°C, verified by infrared thermometer
- Known allergic diseases, in particular asthmatic disorders and skin diseases
- Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: m-Cresol 0.1%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.1%.
|
A preservative administered subcutaneously at 0.1%, a common concentration used in medicines.
|
|
Experimenteel: m-Cresol 0.25%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.25%.
|
A preservative administered subcutaneously at 0.25%, a common concentration used in medicines.
|
|
Placebo-vergelijker: Control solution
Participants receive a 300 µl subcutaneous injection of control solution.
|
A control solution administered subcutaneously.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Area Under the Curve (AUC) of Pain Intensity
Tijdsspanne: From injection start until pain subsides (approximately 15-60 seconds per injection).
|
Total pain burden calculated as the Area Under the Curve of serial pain ratings (0-100 numerical pain rating scale) recorded every 5 seconds from the start of injection until no pain is reported for 30 seconds.
|
From injection start until pain subsides (approximately 15-60 seconds per injection).
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Michael J.M. Fischer, Medical University of Vienna
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EK1688/2024
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ANALYTIC_CODE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .